Other
At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide.
JAMA · 2 Jan 2024
Record
Publication details
- Authors
- Ruder K
- Journal
- JAMA
- Publication date
- 2 Jan 2024
- Publication type
- Journal Article
- Evidence type
- Other
- Relevance classification
- Primary
- PubMed ID
- 38055301
- DOI
- 10.1001/jama.2023.23141
- Language
- eng
- Linked clinical trial
- Not reported
Abstract
This Medical News article discusses weight-loss medications highlighted at ObesityWeek 2023.
Weekly briefing
The Retatrutide Report
The most important retatrutide clinical trial, research and regulatory developments, once a week.
No spam. Unsubscribe anytime. By subscribing, you agree to receive the Retatrutide Report by email. You can unsubscribe at any time. Privacy Policy.